RALLYBIO CORP
RLYB · NASDAQ
Updated at 2026-10-13 11:07:34
- Today's High
- --
- Today’s Low
- --
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $16.88
- Previous Close
- $16.79
- Volume
- 5.97K
- Market Cap
- $89.16M
- P/E Ratio
- 1.95X
- EPS
- $7.88
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 234 CHURCH STREET, NEW HAVEN, CT, UNITED STATES, 06510
- Country
- US
- Listing Date
- 2021-07-29
- Fiscal Year End
- December
- Shares Outstanding
- 5.3M
- CIK
- 0001739410
- Website
- rallybio.com
Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, especially within immunology and hematology. The company boasts a promising pipeline of biologic drug candidates that are currently advancing through clinical trials, backed by an experienced management team with significant industry expertise. By forming strategic partnerships, Rallybio enhances its capacity to deliver transformative treatments in underserved therapeutic areas, demonstrating its commitment to improving patient outcomes. With a well-defined strategy and a robust developmental framework, Rallybio is strategically positioned to achieve significant milestones in the healthcare sector.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$212K
2025-12-31
$222K
2025-09-30
$212K
Operating Expenses
2026-06-30
$5.65M
2026-03-31
$4.94M
2025-12-31
$2.97M
2025-09-30
$2.99M
Net Income
2026-06-30
$43.66M
2026-03-31
-$8.27M
2025-12-31
-$5.85M
2025-09-30
$16.01M
Net Profit Margin
2026-06-30
--
2026-03-31
-3.9K%
2025-12-31
-2.63K%
2025-09-30
7.55K%
Earnings Per Share
2026-06-30
$-1.09
2026-03-31
$-1.46
2025-12-31
$-1.52
2025-09-30
$2.88
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
$44.99M
2026-03-31
-$4.73M
2025-12-31
-$6.4M
2025-09-30
-$6.89M
Effective Tax Rate
2026-06-30
2.94%
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $212K | $222K | $212K |
| Operating Expenses | $5.65M | $4.94M | $2.97M | $2.99M |
| Net Income | $43.66M | -$8.27M | -$5.85M | $16.01M |
| Net Profit Margin | -- | -3.9K% | -2.63K% | 7.55K% |
| Earnings Per Share | $-1.09 | $-1.46 | $-1.52 | $2.88 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | $44.99M | -$4.73M | -$6.4M | -$6.89M |
| Effective Tax Rate | 2.94% | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.